Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Aug 30;7(9):115.
doi: 10.3390/antiox7090115.

The Use of Intravenous Vitamin C as a Supportive Therapy for a Patient with Glioblastoma Multiforme

Nicola Baillie  1 , Anitra C Carr  2 , Selene Peng  3
Affiliations
Case Reports

The Use of Intravenous Vitamin C as a Supportive Therapy for a Patient with Glioblastoma Multiforme

Nicola Baillie et al. Antioxidants (Basel). .

Abstract

Glioblastoma multiforme is a high grade malignant brain tumour with a poor prognosis. Here we report the case of a woman with glioblastoma who lived for over four years from diagnosis (median survival 12 months and 2% survival for three years), experiencing good quality of life for most of that time. She underwent initial debulking craniotomy, radiotherapy and chemotherapy, as well as having intravenous vitamin C infusions 2⁻3 times weekly over the four years from diagnosis. Her progress was monitored by blood tests, regular computerised tomography (CT) and magnetic resonance imaging (MRI) scans, clinical reviews and European Organization for the Research and Treatment of Cancer quality of life questionnaires (EORTC QLQ C30). Our case report highlights the benefits of intravenous vitamin C as a supportive therapy for patients with glioblastoma.

Keywords: ascorbic acid; glioblastoma; intravenous vitamin C; neoplasms; quality of life; vitamin C.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yersal O. Clinical outcome of patients with glioblastoma multiforme: Single center experience. J. Oncol. Sci. 2017;3:123–126. doi: 10.1016/j.jons.2017.10.005. - DOI
    1. Adeberg S., Bostel T., König L., Welzel T., Debus J., Combs S.E. A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: A predictive factor for survival? Radiat. Oncol. 2014;9:1–6. doi: 10.1186/1748-717X-9-95. - DOI - PMC - PubMed
    1. Monti D.A., Mitchell E., Bazzan A.J., Littman S., Zabrecky G., Yeo C.J., Pillai M.V., Newberg A.B., Deshmukh S., Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS ONE. 2012;7:e29794. doi: 10.1371/journal.pone.0029794. - DOI - PMC - PubMed
    1. Welsh J.L., Wagner B.A., van’t Erve T.J., Zehr P.S., Berg D.J., Halfdanarson T.R., Yee N.S., Bodeker K.L., Du J., Roberts L.J., 2nd, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemother. Pharmacol. 2013;71:765–775. doi: 10.1007/s00280-013-2070-8. - DOI - PMC - PubMed
    1. Hoffer L.J., Robitaille L., Zakarian R., Melnychuk D., Kavan P., Agulnik J., Cohen V., Small D., Miller W.H., Jr. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: A Phase I-II clinical trial. PLoS ONE. 2015;10:e0120228. doi: 10.1371/journal.pone.0120228. - DOI - PMC - PubMed

Publication types

LinkOut - more resources